World Vaccines Industry and Market 2015-2025

ワクチンの世界市場:小児用ワクチン、成人用ワクチン

◆タイトル:World Vaccines Industry and Market 2015-2025
◆商品コード:VGAIN5020410
◆調査・発行会社:visiongain
◆発行日:2015年2月
◆ページ数:169
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、ワクチンの世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・ワクチンの世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・ワクチン種類別市場分析
・地域別市場分析
・専門家の見解
・主要企業分析
・結論

Vaccines and their technology – your guide to developments, opportunities and revenues
See what the future holds for vaccines. Visiongain’s updated report lets you assess forecasted sales at overall world market, submarket, product and national level to 2025.

Make sure you understand trends, R&D, opportunities and prospects there, in human medicine. That way you can help your research, analysis and decisions. For those technologies, discover in our study what’s likely to happen. And find what gains are possible.

Vaccines still hold great technological, medical and commercial potential. See why. So please read on to explore that industry and hear what its future market could be worth.

Forecasts from 2015 to 2025 and other analyses showing you commercial prospects
Besides revenue forecasting to 2025, our new work gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).

You also get 50 tables, 49 charts and two interviews, with other opinion. That study includes our discussions with GSK and BiondVax Pharmaceuticals.

Gains through understanding the vaccines sector – find advantages for your work
Leaders hold knowledge. So hear what’s happening for development, production and sales of those preventative medicines. There, from 2015, you see where needs and money exist.

And avoid struggles to gain business information. Instead use our predictions for vaccination to expand your business and help your influence. That way, benefit your authority and stay ahead.

Discover how you and your organisation can gain. The following sections reveal what you get in that new investigation.

Revenues for the world vaccines market and submarkets
What’s that industry’s potential? What’re the secrets of its progress? Discover in our report overall world revenue to 2025. Also find individual forecasts for main submarkets at world level:
• Paediatric vaccines
• Adult vaccines.

How will sales rise? See, then, which product classes can generate most revenue. There you assess prospects for commercial expansion. Discover now the money-earning potential.

Explore the market for vaccinations by brand too.

Forecasts and discussions for leading marketed products
How will leading brands perform to 2025 at world level? Our work shows you 10 individual revenue forecasts to 2025 for top products:
• Prevnar group
• Gardasil
• PENTAct-HIB
• Pediarix
• Varivax/M-M-R II/ProQuad.

And also for these agents:
• Fluzone/Vaxigrip
• Hepatitis group, GSK
• Zostavax
• Pneumovax-23
• RotaTeq.

There you assess potentials, seeing activities, results and outlooks. You discover what’s happening, understanding trends, competition and sales prospects. Assess the future, then, including prospects for newer agents.

Newer vaccines and products in development – how will leading candidates perform?
Also see how newer agents, especially those in development and awaiting launch, can perform. For these 11 medicines, see revenues to 2025:
• Zoster and Malaria vaccines (GSK)
• 9-valent HPV agents (Merck)
• Hexavalent paediatric vaccines (Sanofi)
• Dengue fever products (Sanofi)
• Trumenba vaccines (Pfizer).

And get forecasts for these treatments:
• C. difficile and S. aureus vaccines (Pfizer)
• Ebola vaccines (Johnson & Johnson)
• Dengue fever vaccines (Takeda)
• Universal influenza vaccines (BiondVax).

There you assess the future of that industry’s developments, finding sales gains possible.

Our study also divides its overarching world forecast into geographical regions.

Healthcare in national markets – what outlooks for sales of those medicines?
Progress worldwide in vaccines and healthcare will expand vaccination. You hear about the best revenue prospects for those preventative medicines, getting feel for national prospects.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• European Union (grouped forecast)
• Germany, France, United Kingdom (UK), Italy and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

There you assess developed and developing countries for revenues and potential sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Research and development – explore trends, possibilities and innovations
Our study discusses R&D for immune system modifiers, finding possibilities for technological and commercial advances.

In particular, our report discusses these medical technologies:
• Influenza vaccines
• Prophylactic treatments, including those for meningitis, pneumonia, TB, diphtheria, pertussis, tetanus and rotaviruses
• Protectors against Dengue virus
• Vaccines for HIV, malaria and bacteria
• Prophylaxis in oncology – cancer vaccines – including agents for prostate, pancreatic and lung cancers.

Developments in those immunological treatments hold strength, variety and promise. See what’s possible there for large pharmaceutical companies and biopharma specialists.

Our study explains progress in human prophylaxis, discussing issues to help your work.

Events affecting developers, producers and sellers of vaccines
The report explains forces affecting that industry and market from 2015, including these issues:
• Importance of those products to the pharmaceutical industry
• Immunisation needs and practices in the US
• Medical demands vying with budgetary restraints in Europe
• Rising need in emerging countries and under-developed regions
• Delivery systems, adjuvants and other innovations.

There you explore political, economic, social and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market.

You discover what their present and future hold.

Companies and overall 2019 market value – what revenue possible?
What happens next? Our report predicts the overall world market for vaccines will reach $56.38bn worldwide in 2019, with strong further expansion to 2025.

Find how high its revenues can go. Discover in our work what’s possible for prophylactic medicine and see which companies hold greatest potential.

In particular, you explore these organisations:
• GlaxoSmithKline (GSK)
• Sanofi
• Pfizer
• Johnson & Johnson
• AstraZeneca
• Takeda
• Merck & Co.

From 2015 to 2025 vaccines will benefit patients, payers and companies. Our analysis predicts technological and commercial advances there. Stay ahead by using that work.

【レポートの目次】

1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Main Questions Answered by this Analysis
1.4 Who is this Study for?
1.5 Methods of Research and Analysis
1.6 Frequently Asked Questions (FAQs)
1.7 Some Associated Reports
1.8 About Visiongain

2. Introduction to the World Human Vaccines Market
2.1 Human World Vaccines – Aiming for Global Disease Prevention
2.2 Vaccine Technology
2.2.1 Inactivated Vaccines
2.2.2 Live Attenuated Vaccines
2.2.3 Conjugate Vaccines
2.2.4 Recombinant Vector Vaccines
2.3 Human World Vaccines – Market Segmentation
2.4 Paediatric Vaccines
2.5 Adolescent Vaccines
2.6 Adult Vaccines
2.7 Elderly Vaccines
2.8 Blurred Lines

3. World Vaccine Market Outlook, 2015-2025
3.1 World Vaccine Market, 2014
3.2 World Vaccine Market Forecast: 2015-2025
3.3 World Vaccine Market: Industry Trends, 2015-2025
3.3.1 Demand-Side Trends
3.3.2 Supply-Side Trends
3.3.3 Funding Trends
3.3.4 Decreasing Number of Lower Income Countries (LICs)

4. World Vaccine Submarkets: Prospects, 2015-2025
4.1 Paediatric Vaccines
4.1.1 Paediatric Vaccine Forecast: 2015-2025
4.1.2 Paediatric Vaccine Trends
4.1.2.1 Novel Delivery
4.1.2.2 Fear Factor
4.1.2.3 Novel Vectors
4.1.3 Paediatric Vaccine R&D Pipeline
4.2 Adult Vaccines
4.2.1 Adult Vaccine Forecast: 2015-2025
4.2.2 Adult Vaccine Trends
4.2.2.1 Treat the Untreatable
4.2.2.2 ‘Tis the Season
4.2.2.3 Exotic Killers
4.2.3 Adult Vaccine R&D Pipeline

5. Leading Vaccines: Revenue Predictions to 2025
5.1 Prevnar-13 – Pfizer: Sales Forecasting and Discussions, 2014-2025
5.2 Gardasil – Merck: Sales Forecasting and Discussions, 2014-2025
5.3 PENTAct-HIB – Sanofi: Sales Forecasting and Discussions, 2014-2025
5.4 Pediarix – GSK: Sales Forecasting and Discussions, 2014-2025
5.5 Varivax/M-M-R II/ProQuad – Merck: Sales Forecasting and Discussions, 2014-2025
5.6 Fluzone/Vaxigrip – Sanofi: Sales Forecasting and Discussions, 2014-2025
5.7 Hepatitis Vaccine Franchise – GSK: Sales Forecasting and Discussions, 2014-2025
5.8 Zostavax – Merck: Sales Forecasting and Discussions, 2014-2025
5.9 Pneumovax 23–Merck: Sales Forecasting and Discussions, 2014-2025
5.10 RotaTeq – Merck: Sales Forecasting and Discussions, 2014-2025

6. Leading National Vaccines Markets: 2015-2025
6.1 Human Vaccines: Leading Markets, 2013, 2019 and 2025
6.2 The US Vaccine Market: 2015-2025
6.2.1 The US Vaccine Market: 2014
6.2.2 The US Vaccine Market Forecast: 2015-2025
6.2.3 Obama Healthcare Reform – Benefits for Vaccine Sales
6.3 The Japanese Vaccine Market: 2015-2025
6.3.1 The Japanese Vaccine Market: 2014
6.3.2 The Japanese Vaccine Market Forecast: 2015-2025
6.3.3 Breaking Barriers
6.4 European Union (EU) Vaccine Market: 2015-2025
6.4.1 EU Vaccine Market: 2014
6.4.2 EU Vaccines Market Forecast: 2015-2025
6.4.3 Europe’s Crises
6.5 The German Vaccine Market: 2015-2025
6.5.1 The German Vaccine Market: 2014
6.5.2 The German Vaccine Market Forecast: 2015-2025
6.5.3 Pricey Business
6.6 The French Vaccine Market: 2015-2025
6.6.1 The French Vaccine Market: 2014
6.6.2 The French Vaccine Market Forecast: 2015-2025
6.6.3 French Healthcare System – Events, Policies and Effects
6.7 The UK Vaccine Market: 2015-2025
6.7.1 The UK Vaccine Market: 2014
6.7.2 The UK Vaccine Market: 2015-2025
6.8 The Italian Vaccine Market: 2015-2025
6.8.1 The Italian Vaccine Market: 2014
6.8.2 The Italian Vaccine Market Forecast: 2015-2025
6.8.3 Crumbling Foundation – Challenges in Public Healthcare
6.9 The Spanish Vaccine Market: 2015-2025
6.9.1 The Spanish Vaccine Market: 2014
6.9.2 The Spanish Vaccine Market Forecast: 2015-2025
6.9.3 District Rules – Economic Challenges
6.10 The Brazilian Vaccine Market: 2015-2025
6.10.1 The Brazilian Vaccine Market: 2014
6.10.2 The Brazilian Vaccine Market Forecast: 2015-2025
6.10.3 Dengue Focus
6.11 The Russian Vaccine Market: 2015-2025
6.11.1 The Russian Market: 2014
6.11.2 The Russian Vaccine Market Forecast: 2015-2025
6.11.3 Power of the State
6.12 The Indian Vaccine Market: 2015-2025
6.12.1 The Indian Vaccine Market: 2014
6.12.2 The Indian Vaccine Market Forecast: 2015-2025
6.12.3 Slow Adoption of Vaccines – How Much Progress Possible?
6.13 The Chinese Vaccine Market: 2015-2025
6.13.1 The Chinese Vaccine Market: 2014
6.13.2 The Chinese Vaccine Market Forecast: 2015-2025
6.13.3 Domestic Vaccine Producers and High National Demand

7. Leading Manufacturers of Vaccines for Human Use
7.1 GlaxoSmithKline (GSK)
7.1.1 GSK Vaccine Performance
7.1.2 GSK Developments
7.1.2.1 Mergers and Acquisitions
7.1.2.2 GSK Vaccine Pipeline
7.2 Merck & Co.
7.2.1 Merck Vaccine Performance
7.2.2 Merck Developments
7.2.2.1 Merck Market Movements
7.2.2.2 Collaborations
7.2.2.3 Merck Pipeline
7.3 Sanofi
7.3.1 Sanofi Vaccine Performance
7.3.2 Sanofi Developments
7.3.2.1 Mergers & Acquisitions
7.3.2.2 Sanofi Vaccine Pipeline
7.4 Pfizer
7.4.1 Pfizer Vaccine Performance
7.4.2 Pfizer Developments
7.4.2.1 Pfizer Mergers & Acquisitions
7.4.2.2 Pfizer Pipeline
7.5 Johnson & Johnson
7.6 AstraZeneca
7.7 Other Contenders

8. Qualitative Analysis of the World Vaccines Industry and Market: 2015
8.1 SWOT Analysis of the World Vaccines Industry and Market: 2015-2025
8.1.1 Strengths
8.1.1.1 Ageing Population
8.1.1.2 Strong Research and Development Pipeline
8.1.1.3 Viral Disease Prevention is Crucial
8.1.1.4 Continuing Product Development
8.1.2 Weaknesses
8.1.2.1 R&D Costs
8.1.2.2 Barriers to Market Entry
8.1.3 Opportunities
8.1.3.1 Technological Advances to Protect People from Diseases
8.1.3.2 Vaccine Delivery – Innovations and Opportunities for Improvements
8.1.3.3 Adult Vaccines – High Need
8.1.4 Threats
8.1.4.1 Regulatory Scrutiny Daunting for Some Developers and Marketers
8.1.4.2 Productivity Gap
8.2 STEP Analysis of the World Vaccines Industry and Market: 2015
8.2.1 Social Factors
8.2.1.1 Healthcare Benefits from those Products
8.2.1.2 Public Fears – Resistance from Some Quarters
8.2.2 Technological Forces
8.2.2.1 Technological Improvements to Sustain that Industry’s Success
8.2.3 Economic Factors
8.2.3.1 Costs of Research and Development and Need for Large Vaccine Markets
8.2.3.2 Rising Demand from Less Economically Developed Countries
8.2.4 Political Forces
8.2.4.1 Governmental Influence Shaping the Vaccines Market

9. Opinions from Our Industry Survey
9.1 Progress Statement from GlaxoSmithKline, January 2015
9.1.1 GSK Ebola Vaccine Candidate – Results and Plans
9.2 Interview with Dr Louis J. Picker, Oregon Health and Science University
9.2.1 Challenges of DNA/Ad Vector Vaccines
9.2.2 Broadly Neutralising Antibodies for HIV
9.2.3 A Third Way? The T-Cell Vaccine Approach
9.2.4 Combinations and Other Strategies for HIV
9.2.5 Getting to the Clinic with Therapeutic and Prophylactic HIV Vaccines
9.3 Interview with Tamar Ben-Yedidia, PhD, Chief Scientific Officer, and Tanya Gottlieb, PhD, Business Development, BiondVax Pharmaceuticals
9.3.1 Progress of BiondVax’s Candidate Vaccine
9.3.2 Trialling the Vaccine as a Primer
9.3.3 Assays for Universal Vaccine Effectiveness
9.3.4 Key Differentiators for BiondVax’s Candidate

10. Conclusions
10.1 Serving Needs in Chronic Diseases – Vital Protective Agents
10.2 The Rise of Japan as a Vaccines Market
10.3 The US to Lose its Dominance in Vaccine Sales?
10.4 Emerging National Markets to Increase in Commercial Prominence
10.5 Strong, Promising Research and Development
10.6 Concluding Remarks

List of Tables
Table 1.1 Selected National Human Vaccines Markets: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2019
Table 1.2 Selected National Human Vaccines Markets: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2025
Table 3.1 Overall World Human Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 4.1 Human Vaccines Sub-Markets: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2013-2025
Table 4.2 The Paediatric Human Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 4.3 The Adult Human Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.1 Human Vaccines Leading Vaccines: Revenues ($bn), 2013
Table 5.2 Prevnar Revenue ($bn), 2010-2013
Table 5.3 Prevnar Family: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.4 Gardasil Revenue ($bn), 2011-2013
Table 5.5 Gardasil: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.6 PENTAct-HIB Revenue ($bn), 2012-2013
Table 5.7 PENTAct-HIB: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.8 Pediarix Revenue ($bn), 2012-2013
Table 5.9 Pediarix: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.10 Varivax/M-M-R II/ ProQuad Revenue ($bn), 2011-2013
Table 5.11 Varivax/M-M-R II/ProQuad: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.12 Fluzone/Vaxigrip Revenue ($bn), 2012-2013
Table 5.13 Fluzone/Vaxigrip: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.14 Hepatitis Family, GSK Revenue ($bn), 2012-2013
Table 5.15 Hepatitis Family, GSK: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.16 Zostavax Revenue ($bn), 2011-2013
Table 5.17 Zostavax: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.18 Pneumovax-23 Revenue ($bn), 2011-2013
Table 5.19 Pneumovax-23: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.20 RotaTeq Revenue ($bn), 2011-2013
Table 5.21 RotaTeq: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 6.1 Human Vaccines Market Revenues ($bn) and Market Shares (%) by Leading Country, 2013, 2019 and 2025
Table 6.2 The US Human Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.3 The Japanese Human Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.4 The EU Human Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.5 The German Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.6 The French Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.7 The UK Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.8 The Italian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.9 The Spanish Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.10 The Brazilian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.11 The Russian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.12 The Indian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 6.13 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
Table 7.1 GSK Regional Vaccines Breakdown ($bn), 2013
Table 7.2 GSK Zoster Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
Table 7.3 GSK Malaria Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
Table 7.4 Merck Nine-Valent HPV Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
Table 7.5 Sanofi Hexavalent Paediatric Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 7.6 Sanofi Dengue Fever Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
Table 7.7 Pfizer Trumenba Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 7.8 Pfizer C. difficile Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2025
Table 7.9 Pfizer S. aureus Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2025
Table 7.10 Johnson & Johnson Ebola Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 7.11 Takeda Dengue Fever Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2025
Table 7.12 BiondVax Universal Influenza Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025

List of Figures
Figure 1.1 Human Vaccines Market Segmentation, 2015-2025
Figure 3.1 Human Vaccines: Leading National Market Shares (%), 2013
Figure 3.2 Human Vaccines: Leading National Market Shares (%), 2014
Figure 3.3 Human Vaccines: World-Market Segmentation (%), 2014
Figure 3.4 Global Human Vaccines Market: Drivers and Restraints, 2015-2025
Figure 4.1 Human Vaccines: Main Submarket Segmentation (%), 2025
Figure 5.1 Prevnar-13 Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.2 Gardasil Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.3 PENTAct-HIB Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.4 Pediarix Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.5 Varivax/M-M-R-II/ProQuad Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.6 Fluzone/Vaxigrip Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.7 Hepatitis Family, GSK: Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.8 Zostavax Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.9 Pneumovax-23 Vaccines Revenue Forecast ($bn), 2014-2025
Figure 5.10 RotaTeq Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.1 Human Vaccine Market Shares (%): Top National Markets, 2013
Figure 6.2 Developed National Markets: Drivers and Restraints, 2015-2025
Figure 6.3 Emerging National Markets: Drivers and Restraints, 2015-2025
Figure 6.4 The US Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.5 The Japanese Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.6 The EU Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.7 The German Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.8 The French Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.9 The UK Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.10 The Italian Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.11 The Spanish Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.12 The Brazilian Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.13 The Russian Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.14 The Indian Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 6.15 The Chinese Human Vaccines Revenue Forecast ($bn), 2014-2025
Figure 7.1 GSK Vaccines Revenue ($bn), 2012-2013
Figure 7.2 GSK Regional Vaccines Breakdown, 2013
Figure 7.3 GSK Zoster Vaccines Revenue Forecast ($bn), 2016-2025
Figure 7.4 GSK Malaria Vaccines Revenue Forecast ($bn), 2016-2025
Figure 7.5 Merck Vaccines Revenue ($bn), 2011-2013
Figure 7.6 GSK Malaria Vaccines Revenue Forecast ($bn), 2016-2025
Figure 7.7 Sanofi Vaccines Revenue ($bn), 2012-2013
Figure 7.8 Sanofi Hexavalent Paediatric Vaccines Revenue Forecast ($bn), 2015-2025
Figure 7.9 Sanofi Dengue Fever Vaccines Revenue Forecast ($bn), 2015-2025
Figure 7.10 Pfizer Trumenba Vaccines Revenue Forecast ($bn), 2015-2025
Figure 7.11 Pfizer C. difficile Vaccines Revenue Forecast ($bn), 2017-2025
Figure 7.12 Pfizer S. aureus Vaccines Revenue Forecast ($bn), 2017-2025
Figure 7.13 Johnson & Johnson Ebola Vaccines Revenue Forecast ($bn), 2015-2025
Figure 7.14 Takeda Dengue Fever Vaccines Revenue Forecast ($bn), 2017-2025
Figure 7.15 BiondVax Universal Influenza Vaccines Revenue Forecast ($bn), 2015-2025
Figure 8.1 SWOT Analysis of the Human Vaccines Market, 2015
Figure 8.2 STEP Analysis of the Human Vaccines Market, 2015
Figure 10.1 World Human Vaccines: Regional Market Shares (%), 2025

【掲載企業】

Aduro Biotech
Advisory Committee for Immunization Practices (ACIP)
Aspen
Astellas
Asterias Biotherapeutics
AstraZeneca
Bavarian Nordic
Baxter
Bayer
Bharat Biotech
Bill & Melinda Gates Foundation
Binnopharm
BiondVax
BravoBio
Cancer Research UK
Center for Biologics Evaluation and Research (CBER)
Centers for Disease Control and Protection (CDC)
China National Biotec Group
China’s National Regulatory Authority (CNRA)
Chinese Food and Drug Administration (CFDA)
Crucell
Developing Countries Vaccine Manufacturers Network (DCVMN)
Dubai Investments PJSC
Eli Lilly
European Medicines Agency (EMA)
Facebook
Food and Drug Administration (FDA)
Fresenius
GlaxoSmithKline (GSK)
Global Alliance for Vaccines and Immunization
Globalpharma
Health Service Bureau
HIV Vaccines Trial Network
immatics
Indian Department of Biotech
InnoPharma
Inovio Pharmaceuticals
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
International Medica Foundation
Inviragen
Johnson & Johnson
Krka
LigoCyte Pharmaceuticals
Lupin Pharmaceutical
Merck & Co.
Ministry of Health, Labour and Welfare
NewLink Genetics
Novartis
Okairos
Pan American Health Alliance (PAHO)
Pfizer
Profectus BioSciences
Regulus Therapeutics
Roche
Rosteh
Sanofi
Servizio Sanitario Nazionale (SSN)
Shanghai BravoBio
Shionogi
Sistema Único de Saúde (SUS)
Takeda
UK National Health Service (NHS)
Unicef
US Department of Health and Human Services (HHS)
World Health Organization (WHO)
Zymeworks

【レポートのキーワード】

小児用ワクチン、成人用ワクチン、研究開発、ワクチンパイプライン

★調査レポート[ワクチンの世界市場:小児用ワクチン、成人用ワクチン] ( World Vaccines Industry and Market 2015-2025 / VGAIN5020410) 販売に関する免責事項
[ワクチンの世界市場:小児用ワクチン、成人用ワクチン] ( World Vaccines Industry and Market 2015-2025 / VGAIN5020410) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆